TAG:
pathology groups
IMPATH Has a Buyer: Genzyme Pays $215 Mil
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
New Competitors Line Up In Oncology Marketplace
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acqui…
Useful Info at War College On Molecular, Lean, et al
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: When the nation’s leading laboratory administrators and pathologists gather in New Orleans on April 27- 28, they will get the best and latest developments in laboratory management. From Aetna’s National Medical Director to the former Chief of the Industry Guidance Branch …
Anatomic Path Trends Portend Deep Changes
By Robert Michel | From the Volume XI No. 1 – January 12, 2004 Issue
CEO SUMMARY: Our biannual review of trends shaping the anatomic pathology profession reveals that a wide range of influences are active. The nation’s healthcare system is undergoing fundamental changes in how it views the quality of health services and how it will favor top-performing p…
2003’s Big Lab Stories Reflect Health Trends
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: At a minimum, 2003 proved to be a year of relative stability for the laboratory industry, as demonstrated by THE DARK REPORT’S “Ten Biggest Lab Stories of 2003.” The year was free of industry-wide crises and scan- dals. That allowed most laboratory administrators and pa…
Lab Marketing Strategy Triggers Legal Concerns
By Robert Michel | From the Volume X No. 16 – December 1, 2003 Issue
CEO SUMMARY: That famous phrase “everyone wants something for nothing” does not describe TennCare Select’s reaction to the “free testing” that Quest Diagnostics is performing for its beneficiaries. TennCare provides a real-world example of how this strategy can put a laboratory at o…
Tamtron Plans Comeback After IMPATH’s Chapt. 11
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
CEO SUMMARY: It was only 21 months ago that IMPATH acquired Tamtron. Both companies had high expectations for the relationship. But with IMPATH now in Chapter 11 bankruptcy and facing an unclear future, Tamtron is now an attractive asset for potential buyers who want to enter the anatomic…
Market Demand for Pathologists Shifts Toward Specialization
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
CEO SUMMARY: Unlike the slack employment market for pathologists seen during the 1990s, there is strong demand for pathologists in this decade. Private pathology group practices now face competition for the best pathology talent. That’s because public lab companies are regularly in the …
Chapter 11 Bankruptcy Filed by IMPATH, Inc.
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
CEO SUMMARY: To the surprise of very few, IMPATH, Inc. filed for Chapter 11 bankruptcy protection. During 2003, most of IMPATH’s key executives departed as different problems within the company became known. IMPATH’s new executive leadership is dealing with a host of difficult issues….
AP’s “High & Mighty” Firms Hit Tough Times
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
CEO SUMMARY: In the years between 1995 and 2002, public companies AmeriPath, DIANON Systems, and IMPATH built revenues and profits at a blistering pace. During this time period, these three firms captured enough market share to do almost $1 billion of anatomic pathology business in 2002. …
CURRENT ISSUE

Volume XXXII, No. 13 – September 15, 2025
The Dark Report examines a new bill that would reform PAMA and avoid reimbursement rate cuts scheduled for January 2026. Clinical laboratory leaders are urged to make their voices heard in Congress. Also, an expert describes how labs can fix pre-analytical errors and avoid disaster.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized